MENOPUR^® is a highly purified mixture of human follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity, the most important hormones for inducing the growth of the follicles that produce ova (eggs). As a human menopausal gonadotropin (hMG), MENOPUR^® is classified as a €œmenotropin.€ Menotropins€”injectable hormones that control the reproductive function€”are one of the most widely used types of infertility medication. MENOPUR^® has undergone additional steps for purification. This state-of-the-art purification process results in fewer injection site reactions and less discomfort for the patient.

What does MENOPUR^® do?

MENOPUR^® stimulates egg follicles to grow within the ovaries.

Who should prescribe MENOPUR^® and monitor my care?

MENOPUR^® should be used only by physicians who are thoroughly familiar with infertility treatment and have adequate monitoring facilities. A reproductive endocrinologist, who is most knowledgeable about fertility treatments, should be managing your care to ensure the best outcome. For a referral to a recognized reproductive endocrinologist, contact the American Society of Reproductive Medicine at 205-978-5000, or online at www.asrm.org.

Who should not use MENOPUR^®

MENOPUR^® should not be used by women who are pregnant or have primary ovarian failure, uncontrolled thyroid and adrenal dysfunction, or an organic intracranial lesion such as a pituitary tumor. Also, women who have abnormal bleeding of undetermined origin, ovarian cysts or enlargement not due to polycystic ovary syndrome, or prior hypersensitivity to menotropins should not use this product. Women whose cause of infertility is other than anovulation should not use MENOPUR^®.

How is MENOPUR^® supplied?

MENOPUR^® comes in a vial as a sterile powder, along with the accompanying sterile diluent. Your doctor may recommend using a specified amount of diluent to dissolve one or more vials of MENOPUR^®.

How do I take MENOPUR^®?

MENOPUR^® is approved for subcutaneous (SC) injection only during IVF. With SC administration, you can self-inject the medication just under the skin using much smaller needles than those used for intramuscular (IM) injection.

When should I take MENOPUR^®?

After you and your partner undergo a thorough exam to determine the cause of infertility, your doctor will then recommend a course of action and may prescribe MENOPUR^® alone or in conjunction with a follicle-stimulating hormone (FSH), such as BRAVELLE^®. (Learn about BRAVELLE^® on Our Products page.) Treatment usually begins a few days after your period and may continue daily for 7 to 12 days, depending on how long it takes your follicles to mature.

How should I store MENOPUR^®?

Undissolved MENOPUR^®, in powder form, should be stored in the refrigerator or at room temperature and is good until the expiration date printed on the vial. The product should be protected from light, so store it in its box if possible. Once MENOPUR^® has been dissolved, it should be used immediately and any unused MENOPUR^® should be safely discarded.

Are there side effects?

Like all gonadotropins, MENOPUR^® may produce side effects. Among the most common are abdominal pain, abdominal cramping, nausea, headache, ovarian disease, vaginal hemorrhage, and enlarged abdomen.

A less common but potentially serious side effect associated with all gonadotropin therapy is ovarian hyperstimulation syndrome (OHSS). OHSS occurs in approximately 3.8% of patients who take MENOPUR^®. Please ask your health care provider about this condition.

MENOPUR^® administered subcutaneously is indicated for the development of multiple follicles and pregnancy in the ovulatory patients participating in an ART program.

Important Safety Information

Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe MENOPUR^®. MENOPUR^®, like all gonadotropins, is a potent substance capable of causing mild to severe adverse reactions, including OHSS (overall incidence 3.8%), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. MENOPUR^® is contraindicated in women who have a high FSH level indicating primary ovarian failure; uncontrolled thyroid and adrenal dysfunction; an organic intracranial lesion such as a pituitary tumor; sex hormone dependent tumors of the reproductive tract and accessory organs; abnormal uterine bleeding of undetermined origin; ovarian cysts or enlargement not due to polycystic ovary syndrome; prior hypersensitivity to menotropins or MENOPUR^®. MENOPUR^® is not indicated in women who are pregnant. There are limited human data on the effects of menotropins when administered during pregnancy.